A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

What Was Tested

Researchers studied HMG (Human Menopausal Gonadotropin) in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

Controlled ovarian stimulation with hphMG or rFSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer on day 5 in one fresh or subsequent frozen blastocyst replacement in natural cycles initiated within 1 year of each patient's start of treatment.

How the Study Was Run

In design terms this was a randomized, open-label, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got HMG (Human Menopausal Gonadotropin) and who got the comparison, which limits bias.

Being open-label, the HMG (Human Menopausal Gonadotropin) study did not mask who received what.

More than one site took part, so the participants came from several places.

The HMG (Human Menopausal Gonadotropin) group and the comparison group ran side by side rather than switching.

The methods mention a period of 1 year.

Twenty-five infertility centers in seven countries.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Birth Rate, Europe, Fertility Agents, Female, Follicle Stimulating Hormone, beta Subunit, Gonadotropin-Releasing Hormone and Hormone Antagonists.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of HMG (Human Menopausal Gonadotropin) over 1 year.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Fertility and sterility), a journal based in United States.

More context: the HMG (Human Menopausal Gonadotropin) compound page.